These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 6388952)

  • 21. Effect of administration site in the gastrointestinal tract on bioavailability of poorly absorbed drugs taken after a meal.
    Sakuma S; Tanno FK; Masaoka Y; Kataoka M; Kozaki T; Kamaguchi R; Kokubo H; Yamashita S
    J Control Release; 2007 Mar; 118(1):59-64. PubMed ID: 17250919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic considerations in gastrointestinal motor disorders.
    Hebbard GS; Sun WM; Bochner F; Horowitz M
    Clin Pharmacokinet; 1995 Jan; 28(1):41-66. PubMed ID: 7712661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors contributing to variability in drug pharmacokinetics. I. Absorption.
    Welling PG; Tse FL
    J Clin Hosp Pharm; 1984 Sep; 9(3):163-79. PubMed ID: 6386887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic effects of drug-nutrient interactions in the elderly.
    Roe DA
    J Am Diet Assoc; 1985 Feb; 85(2):174-8, 181. PubMed ID: 3918093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
    Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S
    Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs.
    Koya Y; Uchida S; Machi Y; Shobu Y; Namiki N; Kotegawa T
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1353-1361. PubMed ID: 27491774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.
    Greiff JM; Rowbotham D
    Clin Pharmacokinet; 1994 Dec; 27(6):447-61. PubMed ID: 7882635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.
    Paulson SK; Vaughn MB; Jessen SM; Lawal Y; Gresk CJ; Yan B; Maziasz TJ; Cook CS; Karim A
    J Pharmacol Exp Ther; 2001 May; 297(2):638-45. PubMed ID: 11303053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors responsible for reduced pharmacological activity in rats of pentetrazol administered orally.
    Vohland HW; Zufelde H
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Jun; 293(3):277-83. PubMed ID: 958514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meal energy density as a determinant of postprandial gastrointestinal adaptation in man.
    Wisén O; Hellström PM; Johansson C
    Scand J Gastroenterol; 1993 Aug; 28(8):737-43. PubMed ID: 7692589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactions and non-interactions with ranitidine.
    Kirch W; Hoensch H; Janisch HD
    Clin Pharmacokinet; 1984; 9(6):493-510. PubMed ID: 6096071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simulating the postprandial stomach: physiological considerations for dissolution and release testing.
    Koziolek M; Garbacz G; Neumann M; Weitschies W
    Mol Pharm; 2013 May; 10(5):1610-22. PubMed ID: 23506381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects.
    Zimmermann T; Yeates RA; Albrecht M; Laufen H; Wildfeuer A
    Int J Clin Pharmacol Res; 1994; 14(3):87-93. PubMed ID: 7883389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
    Lincoln J; Stewart ME; Preskorn SH
    J Psychiatr Pract; 2010 Mar; 16(2):103-14. PubMed ID: 20511734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug interactions in the GI tract.
    Black CD; Popovich NG; Black MC
    Am J Nurs; 1977 Sep; 77(9):1426-9. PubMed ID: 18935
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats.
    Lee HT; Lee YJ; Chung SJ; Shim CK
    Res Commun Mol Pathol Pharmacol; 2000; 108(5-6):311-23. PubMed ID: 11958284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Companion animal physiology and dosage form performance.
    Sutton SC
    Adv Drug Deliv Rev; 2004 Jun; 56(10):1383-98. PubMed ID: 15191788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How food and fluid affect drug absorption: results of initial studies.
    Welling PG
    Postgrad Med; 1977 Jul; 62(1):73-82. PubMed ID: 876907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability of erythromycin stearate: influence of food and fluid volume.
    Welling PG; Huang H; Hewitt PF; Lyons LL
    J Pharm Sci; 1978 Jun; 67(6):764-6. PubMed ID: 660450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.